inappropriately concentrated urine with normal sodium excretion levels, and the absence of interfering medications, hypothyroidism and adrenal insufficiency. 6 Treatment of SIADH is traditionally determined by acuity of onset (within the last 48 hours), presence/absence of symptoms, and biochemical severity of hyponatraemia. The European Clinical Practice Guidelines use the terminology "profound" hyponatraemia to denote a serum sodium <125 mmol/L and "severe" to describe the symptomatology. 6 Unless hypertonic saline is indicated for acute onset profound hyponatraemia and/or with severe symptoms, the mainstay of management has traditionally been fluid restriction, a treatment often difficult to implement practically and effective in less than 50% of patients. 4 Recent European and American guidelines differ in their approach to second-line management. 6, 7 Urea has been used for the treatment of SIADH since the 1980s 8 and case reports/series have demonstrated it is an effective adjunct where fluid restriction is impractical or ineffective. 8, 9 Urea is readily absorbed from the gut and freely filtered at the glomerulus; in a patient with normal renal function, the entirety of a 15 g dose is excreted within 12 hours of ingestion. 13 Administration of urea in the setting of hyponatraemia induces an osmotic diuresis, a reduction in natriuresis, and net free water excretion. 8 Studies in animal models suggest that urea may additionally protect from osmotic demyelination, a rare complication of overly rapid correction of serum sodium. 14 Despite this, it is infrequently used as shown in a multinational hyponatraemia registry of 3087 patients, where only 10 were treated with urea. 4 In a recent audit of the investigation and management of hyponatraemia at our institution, it was noted in a small number of patients that urea was a safe and effective second-line treatment. 15 This in turn led to a departmental change in policy, such that urea was used routinely in cases of SIADH where fluid restriction either had resulted in no or minimal change in serum sodium or was not feasible for other reasons. We hypothesized that urea is a safe, effective treatment for hyponatraemia due to SIADH in fluid restriction-refractory patients, or those unable to be restricted.
| ME THODS
Inpatients with moderate hyponatraemia (serum sodium <130 mmol/L) between December 2015 and December 2017
were identified using the laboratory information system at the Princess Alexandra Hospital, a tertiary referral hospital in Brisbane, Australia. These data were cross-referenced with pharmacy dispensing records for urea to identify all those that were prescribed urea. Exclusion criteria were age <18 years, pregnancy, and pseu- 
| RE SULTS
Urea was used in the treatment of hyponatraemia on 78 occasions in 69 patients. There were 6 patients who received multiple courses with intervening periods of normal serum sodium off treatment. The demographic information of the urea-treated patients is shown in Table 1 . The most common cause of hyponatraemia receiving urea treatment was SIADH, of which the most frequent precipitant was central nervous system pathology (more common than in the com- Table 2 . In 50 treatment episodes (64.1%), the patient achieved a serum sodium ≥130 mmol/L at 72 hours postinitiation of urea treatment, TA B L E 1 Demographics of patients treated with urea (n = 78) and fluid restriction alone (n = 51) (Continues) Seventeen patients (21.8%) had side effects, distaste the most common (7), followed by nausea (6) and hypokalaemia (4). None were severe or led to discontinuation of treatment. Seven patients were admitted to a high-dependency or intensive care unit after initiation of urea treatment, none due to symptomatic hyponatraemia or side effects from the treatment. No patients developed hypernatraemia, overcorrection, osmotic demyelination or died.
| D ISCUSS I ON
Here we reported the second largest case series of urea treatment, and the largest outside of an intensive care setting. We have shown that urea is a safe and effective second-line therapy for those patients in whom fluid restriction has failed or is impractical. The primary outcome of serum sodium ≥130 mmol/L achieved in 64.1% of treatment occasions is higher than any other second-line agent in the multinational hyponatraemia registry for patients who had failed fluid restriction. 4 The improvement in serum sodium after commencement of urea was consistent with that reported in three previous case series (two from intensive care settings) using similar dose ranges. 10, 12, 16 When compared to a contemporaneous group of patients with SIADH who were managed with fluid restriction alone, neither the proportion achieving serum sodium ≥130 mmol/L nor the time to achieve a serum sodium ≥130 or ≥135 mmol/L were significantly different. However, the urea-treated patients were either not able to be fluid restricted or had clearly failed to increment their serum sodium prior to urea initiation ( Figure 1 ). In addition, they required a tighter fluid restriction and had a lower nadir serum sodium, indicative of a self-selected, more severe group. High urine osmolality is a known predictor of failure of fluid restriction as was seen in these patients. 17 The benefits seen from urea treatment were consistent in the three subsets demonstrated in Figure 2 . The European Clinical
Practice Guidelines make the distinction between biochemically profound hyponatraemia (defined as a serum sodium <125 mmol/L) and clinically severe-based on severity of symptoms. 6 In our institution, hypertonic (3%) saline had been often used in patients with a serum sodium <120 mmol/L, even in the absence of severe TA B L E 2 Biochemical parameters for patients treated with urea (n = 78) and fluid restriction alone (n = 51) symptoms. While hypertonic (3%) saline is the treatment of choice in severe symptomatic hyponatraemia, 6, 7 this study has demonstrated the safety and efficacy of using urea in patients with biochemically profound hyponatraemia (<120 mmol/L) without severe symptoms and those with acute onset hyponatraemia with moderate symptoms. Our recently published experience treating moderate to severe hyponatraemia included hypertonic saline for severe symptomatic hyponatraemia where a median increase in serum sodium of 11 mmol/L was observed over the total treatment period. 15 Treatment with urea at our centre was well tolerated, and there were no grade 3/4 toxicities from treatment. The most common side effect of distaste can be ameliorated by mixture with sweet or carbonated liquids (there is a more palatable recipe published), 18 and no patient in our study discontinued treatment as a result of this or any other side effect. The biggest concern with treatment of hyponatraemia is that of overly rapid correction and the subsequent risk of osmotic demyelination syndrome (ODS). Overly rapid correction has been shown to be a risk with use of hypertonic saline 4, 19, 20 and vasopressin receptor antagonists ("vaptans"), 4, 21, 22 and has been seen previously in some urea series, 10, 11 but not oth- Change in serum Na (mmol/L) **** F I G U R E 2 Median (IQR) serum sodium for patients with acute, symptomatic hyponatraemia (n = 10; one-way ANOVA P = 0.0011), serum sodium ≤120 mmol/L at commencement of urea (n = 21; one-way ANOVA P < 0.0001), and those who developed SIADH while being treated on local subarachnoid protocol (3 L 0.9% saline per 24 h; n = 11; one-way ANOVA P = 0.0004) from time of urea treatment initiation. Na, serum sodium; SAH, subarachnoid haemorrhage 
| CON CLUS ION
This study adds to the growing body of evidence that urea is a safe, effective, and well-tolerated treatment for hyponatraemia due to SIADH. Based on our data, we recommend urea in patients with SIADH and moderate to profound hyponatraemia (in the absence of severe These studies are required to clearly elucidate the place for urea in the treatment of SIADH and help form an easy to use algorithm.
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